ClinicalTrials.gg
CompletedNCT07412496Updated Oct 22, 2026

A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy

A Phase 2 interventional study of Topical Ocular BL1332 low dose and Topical Ocular BL1332 high dose in Pain, Postoperative, sponsored by Bausch & Lomb Incorporated. Completed at 15 sites in United States. Open to participants aged 18 Years to 58 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment

Updated Oct 22, 2026Now CompletedFirst site in United States+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 58 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,180 studies in Pain, Postoperative with a site in United States — 203 open to participants now, 236 under way, 25 of them phase 3. Pain, Postoperative · United States.

Enrollment
279th of 1,098
130 · median 76
Started
2026
with 67 others
Phase 2
121 of 1,180
9 open now
Registered
1,130th of 1,180
by date

Among the 1,180 studies in Pain, Postoperative with a site in United States, this one is the 279th largest by enrollment of the 1,098 interventional ones that give a count, is one of 68 that started in 2026, is one of 121 in phase 2, and was the 1,130th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

203 of the 1,180 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:

198 more — sign in →

All 203 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 58 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,180 studies in Pain, Postoperative with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, double-masked study to evaluate the use of Topical Ocular BL1332 for the management of post-operative pain after Photorefractive Keratectomy (PRK) surgery.

03

Conditions studied

  • Pain, Postoperative

Browse trials for

04

Who can participate

Ages eligible
18 Years to 58 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female 18 to 58 years of age, inclusive.
  2. Scheduled to undergo PRK surgery and considered to be a good candidate per the Investigator's discretion.
  3. Provide written (signed and dated informed consent form [ICF]) using the Institutional Review Board (IRB)-approved ICF prior to any study-related procedures.
  4. Able to read, understand, and voluntarily sign the ICF and, if applicable, provide written authorization per local privacy regulations.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded from this study. All criteria are evaluated at Screening unless otherwise specified.

  1. Women of or non-vasectomized males with partners of childbearing potential are not eligible unless they are using an effective method of and agree to use an effective method of contraception until at least 30 days after study treatment.

    a. Male who is unwilling to agree to use at least 1 medically accepted form of birth control with female partner of childbearing potential.

  2. Participation in a clinical trial within 30 days prior to Screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    Topical Ocular BL1332 low dose

    BL1332 low dose ocular drop used 5x daily

    Drug: Topical Ocular BL1332 low dose

  • Experimental
    Topical Ocular BL1332 high dose

    BL1332 high dose ocular drop used 5x daily

    Drug: Topical Ocular BL1332 high dose

  • Placebo comparator
    BL1332 ophthalmic vehicle

    BL1332 vehicle ocular drop used 5x daily

    Drug: BL1332 Vehicle ophthalmic vehicle

Interventions

  • DrugTopical Ocular BL1332 low dose

    Administered 5 times a day

  • DrugTopical Ocular BL1332 high dose

    Administered 5 times a day

  • DrugBL1332 Vehicle ophthalmic vehicle

    Administered 5 times a day

06

What researchers measure

Primary outcomes

  1. Ocular pain intensity following PRK surgery

    Ocular pain intensity assessed using numeric pain rating scale 0 to 10, with 10 being the worst pain

    Time frame: Assessed at a 24-hour period following PRK surgery

Secondary outcomes

  1. Ocular pain intensity postoperative period following PRK surgery

    Ocular pain intensity assessed using numeric pain rating scale 0 to 10, with 10 being the worst pain

    Time frame: Assessed at a 12-hour postoperative period following PRK surgery

07

Study locations

15 sites
  • Site 14
    Scottsdale, Arizona 85250, United States
  • Site 3
    Long Beach, California 90805, United States
  • Site 10
    Pasadena, California 91107, United States
  • Site 11
    San Diego, California 92122, United States
  • Site 15
    Davie, Florida 33324, United States
  • Site 13
    Brookline, Massachusetts 02445, United States
  • Site 5
    Bloomington, Minnesota 55420, United States
  • Site 8
    Amherst, New York 14228, United States
  • Site 9
    Fargo, North Dakota 58103, United States
  • Site 6
    West Fargo, North Dakota 58078, United States
  • Site 1
    Sioux Falls, South Dakota 57108, United States
  • Site 2
    Cedar Park, Texas 78613, United States
  • Site 12
    Draper, Utah 84020, United States
  • Site 4
    Salt Lake City, Utah 84107, United States
  • Site 7
    Lynchburg, Virginia 24502, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in Oct 2026, 6 months.

Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 6 months is below that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Apr 2026 → Mar 2026, primary completion Feb 2027 → Oct 2026 and completion Feb 2027 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 17, 2026
StartActual
Mar 31, 2026was Apr 2026
Primary completionActual
Oct 4, 2026was Feb 2027
CompletionActual
Oct 4, 2026was Feb 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 22, 2026
Sites
15 sites added — first site in United States
Show 15 added (15 United States)
  • Site 14 · Scottsdale, United States
  • Site 3 · Long Beach, United States
  • Site 10 · Pasadena, United States
  • Site 11 · San Diego, United States
  • Site 15 · Davie, United States
  • Site 13 · Brookline, United States
  • Site 5 · Bloomington, United States
  • Site 8 · Amherst, United States
  • Site 9 · Fargo, United States
  • Site 6 · West Fargo, United States
  • Site 1 · Sioux Falls, United States
  • Site 2 · Cedar Park, United States
  • Site 12 · Draper, United States
  • Site 4 · Salt Lake City, United States
  • Site 7 · Lynchburg, United States
Oct 22, 2026
Start date
Apr 2026→Mar 31, 2026 (actual)
Oct 22, 2026
Primary completion
Feb 2027→Oct 4, 2026 (actual)
Oct 22, 2026
Study completion
Feb 2027→Oct 4, 2026 (actual)
Oct 22, 2026
Enrollment
123 (estimated)→130 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Not yet recruiting→Completed
    15 sites added — first site in United States
    Show 15 added (15 United States)
    • Site 14 · Scottsdale, United States
    • Site 3 · Long Beach, United States
    • Site 10 · Pasadena, United States
    • Site 11 · San Diego, United States
    • Site 15 · Davie, United States
    • Site 13 · Brookline, United States
    • Site 5 · Bloomington, United States
    • Site 8 · Amherst, United States
    • Site 9 · Fargo, United States
    • Site 6 · West Fargo, United States
    • Site 1 · Sioux Falls, United States
    • Site 2 · Cedar Park, United States
    • Site 12 · Draper, United States
    • Site 4 · Salt Lake City, United States
    • Site 7 · Lynchburg, United States
    Start date Apr 2026→Mar 31, 2026 (now actual)
    Primary completion Feb 2027→Oct 4, 2026 (now actual)
    Study completion Feb 2027→Oct 4, 2026 (now actual)
    Enrollment 123 (estimated)→130 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07412496
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Mar 31, 2026
Primary completion
Oct 4, 2026
Completion
Oct 4, 2026
Last update
Oct 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion